Acadia Pharma (ACAD): Nuplazid KOL Follow-Up Call - Needham
- Wall Street again marks new highs in post-election run
- Broadcom Ltd. (AVGO) Tops Q4 EPS by 11c
- Restoration Hardware (RH) Tops Q3 EPS by 4c; Guides Well Below the Street
- Unusual 11 Mid-Day Movers 12/8: (COOL) (TLRD) (DRAM) Higher; (SHIP) (OHRP) (MLSS) Lower
- After-Hours Stock Movers 12/08: (FNSR) (AVGO) (GLPG) Higher; (XTLY) (RH) (DLTH) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Needham & Company analyst, Alan Carr, reiterated his Buy rating on shares of Acadia Pharmaceuticals (NASDAQ: ACAD) after hosting a call last week with KOL Joseph Friedman of Brown University/Butler Hospital to discuss his experience with Nuplazid.
The drug was approved by FDA for Parkinson’s Disease Psychosis in Apr and launched in May 2016. Dr. Friedman has prescribed Nuplazid for ~15 pts to date. Initial feedback from 9 pts indicates the drug has been helpful in treatment-naive pts (3/4), but not in pts who have previously responded poorly to traditional antipsychotics (0/5).
Dr. Friedman has been impressed w/ safety and tolerability profile and plans to use the drug as front-line therapy. Because onset of action is relatively slow (3-6wks), he plans to continue to use quetiapine or clozapine in pts who need psychosis symptoms addressed immediately. There have been no major hurdles w/ payer coverage.
No change to the price target of $49.
Shares of Acadia Pharmaceuticals closed at $25.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Reiterates Buy on Ciena (CIEN) Following 4Q Report
- UPDATE: Stifel Downgrades CEB Inc (CEB) to Hold
- UPDATE: Stifel Downgrades Lincoln Electric (LECO) to Hold
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesNeedham & Company, Alan Carr
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!